ClinicalTrials.gg
RecruitingNCT07569588IMPACT-AKIUpdated May 6, 2026

Improving Patient Assessment After Acute Kidney Injury (AKI)

An observational study in Acute Kidney Injury, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Nottingham · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Acute Kidney Injury with a site in United Kingdom — 16 open to participants now, 21 under way, none of them phase 3. Acute Kidney Injury · United Kingdom.

Planned enrollment
29th of 46
100 · median 243
Started
2026
with 6 others
Observational
46 of 77
8 open now
Primary completion
2028-01
later than 18 of 20 live
Registered
73rd of 77
by date
Lead sponsor
3 of 77
University of Nottingham

Among the 77 studies in Acute Kidney Injury with a site in United Kingdom, this one is the 29th largest by planned enrollment of the 46 observational ones that give a count, is one of 7 that started in 2026, is one of 46 observational ones, reaches primary completion later than 18 of the 20 other live ones, and was the 73rd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

16 of the 77 studies in Acute Kidney Injury with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Acute Kidney Injury with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are:

  1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI?
  2. What are the experiences of patients after AKI?
  3. What interventions should be recommended to improve assessment and support of patients after AKI?

Participants will be asked to do one or more of:

  • blood tests to measure kidney function in different ways
  • have measurement of their body composition
  • complete questionnaires about their symptoms
  • have an interview with a researcher about their experiences
  • discussion to develop an action plan based on findings
03

Conditions studied

  • Acute Kidney Injury

Keywords

  • acute kidney injury
  • chronic kidney disease
  • patient reported outcome measures
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Observational study workstream: secondary care nephrology clinics Qualitative interview workstream: secondary care nephrology clinics, hospitalised patients with AKI not followed up in nephrology clinic, participants of other aspects of the study.

Participatory workshop workstream: Organisational and professional organisations with interest in acute kidney injury, professional networks, public and patient involvement and engagement groups

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Observational study workstream

  • Age 18-85 years
  • AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission
  • 60-90 days after peak creatinine Qualitative interview workstream
  • Age 18-85 years
  • AKI during hospital admission
  • 60-90 days after peak creatinine Participatory workshop workstream
  • Age 18-85 years
  • Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community.

Exclusion criteria

Exclusion Criteria:

Observational study workstream

  • Inability to give
  • No baseline creatinine available in previous 12 months
  • Pregnancy or breastfeeding
  • Current treatment with dialysis
  • Renal transplant
  • Pacemaker in situ
  • Previous amputation
  • Allergy to Omnipaque contrast agent (WP1 only)
  • Manifest thyrotoxicosis (WP1 only)
  • Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for >1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream
  • Inability to give informed consent
  • No baseline creatinine available in previous 12 months
  • Current treatment with dialysis
  • Renal transplant
  • Receiving palliative care Participatory workshop workstream
  • Inability to give informed consent
  • Inability to communicate in English (the qualitative workshops will be held in English)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Observational study

    Patients 3 months after hospitalised acute kidney injury

    Diagnostic Test: Iohexol renal clearance measurement · Diagnostic Test: Cystatin C · Diagnostic Test: Creatinine · Diagnostic Test: Metagenome analysis · Diagnostic Test: Bioimpedance analysis · Other: Patient reported outcome measures · Other: Measurement of physical performance

  • Qualitative study

    Patients 3 months after hospitalised acute kidney injury

    Other: Semi structured interview

  • Participatory workshops

    Individuals with personal or professional experience of acute kidney injury

    Other: Participatory workshop

Interventions

  • Diagnostic testIohexol renal clearance measurement

    Gold standard measurement of glomerular filtration rate.

  • Diagnostic testCystatin C

    Estimated GFR using serum cystatin C

  • Diagnostic testCreatinine

    eGFR from serum creatinine level

  • OtherSemi structured interview

    Semi structured interview to explore patient experiences. Purposive sampling will be used to explore a wide range of perspectives and transcripts will be analysed using thematic analysis to develop codes and themes.

  • OtherParticipatory workshop

    Group workshop using qualitative methods. Purposive sampling will be used to explore a wide range of perspectives and transcripts will be analysed using thematic analysis to develop codes and themes. These will be used to develop consensus recommendations.

  • Diagnostic testMetagenome analysis

    Analysis of the metagenome using faecal samples of participants after acute kidney injury

  • Diagnostic testBioimpedance analysis

    Estimation of body composition

  • OtherPatient reported outcome measures

    EQ-5D-5L, KSQ, WHO-DAS 2.0, K10

  • OtherMeasurement of physical performance

    Hand grip, Short physical performance battery

06

What researchers measure

Primary outcomes

  1. The proportion of eligible patients who agree to participate

    Time frame: 3 months

  2. The proportion of participants who have all three measurements (eGFR-cystatin, eGFR-creatinine and measured GFR)

    Time frame: 3 months

  3. Standard deviation of the difference between measured GFR and eGFR-creatinine and eGFR-cystatin

    Time frame: 3 months

  4. The proportion of patients with eGFR <60ml/min/1.73m2 from eGFR-cystatin compared with eGFR creatinine

    Time frame: 3 months

  5. Gut microbiome composition

    Assessed through metagenomics

    Time frame: 3 months

  6. Codes and themes related to patient experience after AKI, identified from systematic qualitative analysis of interview transcripts

    Time frame: 3 - 12 months

  7. Production of a document of recommended next steps through MDT development during participatory workshops

    Time frame: At completion of third workshop 3 years after enrolment

Secondary outcomes

  1. The mean difference between eGFR-cystatin and eGFR-creatinine

    Time frame: 3 months

  2. The mean difference between iohexol measured GFR and each estimated GFR method (creatinine and cystatin)

    Time frame: 3 months

  3. Correlation between eGFR creatinine and eGFR cystatin

    Time frame: 3 months

  4. Correlation between iohexol measured GFR and each estimated GFR method (creatinine and cystatin)

    Time frame: 3 months

  5. Bias between iohexol measured GFR and each estimated GFR method (creatinine and cystatin)

    Time frame: 3 months

  6. Accuracy of eGFR creatinine and eGFR cystatin compared with iohexol measured GFR as assessed by the percentage of estimated values within 30% of measured GFR (P30)

    Time frame: 3 months

  7. Correlation of muscle mass with the percentage difference between eGFR-cystatin and eGFR-creatinine

    Time frame: 3 months

  8. Correlation of physical function with the percentage difference between eGFR-cystatin and eGFR-creatinine

    Time frame: 3 months

  9. Correlation of patient reported outcomes with the percentage difference between eGFR-cystatin and eGFR-creatinine

    Time frame: 3 months

  10. Barriers to implementation of recommendations as identified through MDT discussion at participatory workshops

    Time frame: At completion of third workshop 3 years after enrolment

Other outcomes

  1. Safety Outcomes

    * Adverse events spontaneously reported during the study * Discontinuation due to adverse events

    Time frame: From enrolment until the end of study visits (from 3 to 12 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — IPD sharing will be available on request through the study team and individual applications will be considered.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 23 months is close to that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
May 6, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Oct 2029
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569588
Collaborators
University Hospitals of Derby and Burton NHS Foundation Trust
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Feb 16, 2026
Primary completion
Jan 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
May 6, 2026

Study contacts

Kerry Horne Dr, BMBCh
Contact
kerry.horne@nottingham.ac.uk
+44 01332 788262
Nicholas Selby
principal investigator · University of Nottingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion